Summary:

- This article discusses a gene therapy breakthrough that is restoring sight to people who were previously blind. The therapy, called Luxturna, targets a rare genetic mutation that causes a form of inherited blindness called Leber congenital amaurosis.

- The gene therapy involves injecting a healthy copy of the affected gene directly into the retina, which then produces the necessary protein to restore vision. Clinical trials have shown that the treatment can significantly improve vision in patients, with some regaining the ability to read, navigate, and perform other visual tasks.

- The success of Luxturna highlights the potential of gene therapy to treat a wide range of genetic disorders, and it represents a significant milestone in the field of ophthalmology and personalized medicine. The article emphasizes the transformative impact this treatment can have on the lives of people living with inherited blindness.